Metabolic Profiling of Female Tg2576 Mouse Brains Provides Novel Evidence Supporting Intranasal Low-Dose Pioglitazone for Long-Term Treatment at an Early Stage of Alzheimer’s Disease

Accumulating evidence suggests that disruptions in brain energy metabolism may be a key player in the pathogenesis of Alzheimer’s disease (AD). Pioglitazone (PIO) has been found to exert beneficial effects on metabolic dysfunction in many AD preclinical studies. However, limited success in clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Wong, Ling Rong, Wong, Peiyan, Ho, Paul Chi-Lui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764407/
https://www.ncbi.nlm.nih.gov/pubmed/33317213
http://dx.doi.org/10.3390/biomedicines8120589

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7764407/
https://www.ncbi.nlm.nih.gov/pubmed/33317213
http://dx.doi.org/10.3390/biomedicines8120589

Ejemplares similares